276 related articles for article (PubMed ID: 29122992)
1. Labile plasma iron levels predict survival in patients with lower-risk myelodysplastic syndromes.
de Swart L; Reiniers C; Bagguley T; van Marrewijk C; Bowen D; Hellström-Lindberg E; Tatic A; Symeonidis A; Huls G; Cermak J; van de Loosdrecht AA; Garelius H; Culligan D; Macheta M; Spanoudakis M; Panagiotidis P; Krejci M; Blijlevens N; Langemeijer S; Droste J; Swinkels DW; Smith A; de Witte T;
Haematologica; 2018 Jan; 103(1):69-79. PubMed ID: 29122992
[TBL] [Abstract][Full Text] [Related]
2. Dyserythropoiesis evaluated by the RED score and hepcidin:ferritin ratio predicts response to erythropoietin in lower-risk myelodysplastic syndromes.
Park S; Kosmider O; Maloisel F; Drenou B; Chapuis N; Lefebvre T; Karim Z; Puy H; Alary AS; Ducamp S; Verdier F; Bouilloux C; Rousseau A; Jacob MC; Debliquis A; Charpentier A; Gyan E; Anglaret B; Leyronnas C; Corm S; Slama B; Cheze S; Laribi K; Amé S; Rose C; Lachenal F; Toma A; Pica GM; Carre M; Garban F; Mariette C; Cahn JY; Meunier M; Herault O; Fenaux P; Wagner-Ballon O; Bardet V; Dreyfus F; Fontenay M
Haematologica; 2019 Mar; 104(3):497-504. PubMed ID: 30287621
[TBL] [Abstract][Full Text] [Related]
3. Iron overload across the spectrum of non-transfusion-dependent thalassaemias: role of erythropoiesis, splenectomy and transfusions.
Porter JB; Cappellini MD; Kattamis A; Viprakasit V; Musallam KM; Zhu Z; Taher AT
Br J Haematol; 2017 Jan; 176(2):288-299. PubMed ID: 27917462
[TBL] [Abstract][Full Text] [Related]
4. Serum hepcidin measured with an improved ELISA correlates with parameters of iron metabolism in patients with myelodysplastic syndrome.
Zipperer E; Post JG; Herkert M; Kündgen A; Fox F; Haas R; Gattermann N; Germing U
Ann Hematol; 2013 Dec; 92(12):1617-23. PubMed ID: 23842708
[TBL] [Abstract][Full Text] [Related]
5. Serum iron metabolism and erythropoiesis in patients with myelodysplastic syndrome not receiving RBC transfusions.
Cui R; Gale RP; Zhu G; Xu Z; Qin T; Zhang Y; Huang G; Li B; Fang L; Zhang H; Pan L; Hu N; Qu S; Xiao Z
Leuk Res; 2014 May; 38(5):545-50. PubMed ID: 24598841
[TBL] [Abstract][Full Text] [Related]
6. Second international round robin for the quantification of serum non-transferrin-bound iron and labile plasma iron in patients with iron-overload disorders.
de Swart L; Hendriks JC; van der Vorm LN; Cabantchik ZI; Evans PJ; Hod EA; Brittenham GM; Furman Y; Wojczyk B; Janssen MC; Porter JB; Mattijssen VE; Biemond BJ; MacKenzie MA; Origa R; Galanello R; Hider RC; Swinkels DW
Haematologica; 2016 Jan; 101(1):38-45. PubMed ID: 26385212
[TBL] [Abstract][Full Text] [Related]
7. Clinical relevance of anemia and transfusion iron overload in myelodysplastic syndromes.
Cazzola M; Della Porta MG; Malcovati L
Hematology Am Soc Hematol Educ Program; 2008; ():166-75. PubMed ID: 19074076
[TBL] [Abstract][Full Text] [Related]
8. Residual erythropoiesis protects against myocardial hemosiderosis in transfusion-dependent thalassemia by lowering labile plasma iron via transient generation of apotransferrin.
Garbowski MW; Evans P; Vlachodimitropoulou E; Hider R; Porter JB
Haematologica; 2017 Oct; 102(10):1640-1649. PubMed ID: 28642302
[TBL] [Abstract][Full Text] [Related]
9. Iron overload in myelodysplastic syndromes.
Mahesh S; Ginzburg Y; Verma A
Leuk Lymphoma; 2008 Mar; 49(3):427-38. PubMed ID: 18297518
[TBL] [Abstract][Full Text] [Related]
10. SF3B1-mutated myelodysplastic syndrome with ring sideroblasts harbors more severe iron overload and corresponding over-erythropoiesis.
Zhu Y; Li X; Chang C; Xu F; He Q; Guo J; Tao Y; Liu Y; Liu L; Shi W
Leuk Res; 2016 May; 44():8-16. PubMed ID: 26970172
[TBL] [Abstract][Full Text] [Related]
11. The evaluation of iron overload through hepcidin level and its related factors in myelodysplastic syndromes.
Gu S; Song X; Zhao Y; Guo J; Fei C; Xu F; Wu L; Zhang X; Zhao J; Chang C; Li X
Hematology; 2013 Sep; 18(5):286-94. PubMed ID: 23540794
[TBL] [Abstract][Full Text] [Related]
12. [Detection of Hepcidin in transfusion dependent myelodysplastic syndrome patients and its clinical significance].
Qin Y; Liu H; Ruan S; Cai YF; You XF; Song GQ
Zhonghua Xue Ye Xue Za Zhi; 2011 Nov; 32(11):758-61. PubMed ID: 22339912
[TBL] [Abstract][Full Text] [Related]
13. Hepcidin levels and their determinants in different types of myelodysplastic syndromes.
Santini V; Girelli D; Sanna A; Martinelli N; Duca L; Campostrini N; Cortelezzi A; Corbella M; Bosi A; Reda G; Olivieri O; Cappellini MD
PLoS One; 2011; 6(8):e23109. PubMed ID: 21886780
[TBL] [Abstract][Full Text] [Related]
14. Impact of transfusion dependency and secondary iron overload on the survival of patients with myelodysplastic syndromes.
Malcovati L
Leuk Res; 2007 Dec; 31 Suppl 3():S2-6. PubMed ID: 18037415
[TBL] [Abstract][Full Text] [Related]
15. When is iron overload deleterious, and when and how should iron chelation therapy be administered in myelodysplastic syndromes?
Steensma DP; Gattermann N
Best Pract Res Clin Haematol; 2013 Dec; 26(4):431-44. PubMed ID: 24507819
[TBL] [Abstract][Full Text] [Related]
16. Interaction of Transfusion and Iron Chelation in Thalassemias.
Porter JB; Garbowski MW
Hematol Oncol Clin North Am; 2018 Apr; 32(2):247-259. PubMed ID: 29458730
[TBL] [Abstract][Full Text] [Related]
17. Treatment of transfusional iron overload in patients with myelodysplastic syndrome or severe anemia: data from multicenter clinical practices.
Raptis A; Duh MS; Wang ST; Dial E; Fanourgiakis I; Fortner B; Paley C; Mody-Patel N; Corral M; Scott J
Transfusion; 2010 Jan; 50(1):190-9. PubMed ID: 19719471
[TBL] [Abstract][Full Text] [Related]
18. Increased serum hepcidin levels during treatment with deferasirox in iron-overloaded patients with myelodysplastic syndrome.
Ghoti H; Fibach E; Westerman M; Gordana O; Ganz T; Rachmilewitz EA
Br J Haematol; 2011 Apr; 153(1):118-20. PubMed ID: 21332711
[TBL] [Abstract][Full Text] [Related]
19. Liver iron concentrations and urinary hepcidin in beta-thalassemia.
Origa R; Galanello R; Ganz T; Giagu N; Maccioni L; Faa G; Nemeth E
Haematologica; 2007 May; 92(5):583-8. PubMed ID: 17488680
[TBL] [Abstract][Full Text] [Related]
20. Iron overload in myelodysplastic syndromes (MDS).
Gattermann N
Int J Hematol; 2018 Jan; 107(1):55-63. PubMed ID: 29177643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
